“Micro” Extrathyroidal Extension in Risk Stratification for Papillary Thyroid Carcinoma: Should It Be in the Intermediate-Risk or High-Risk Group? A Single-Center Retrospective Study

References

• Li M, Dal Maso L, Vaccarella S. Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol. 2020;8(6):468–470. doi:10.1016/S2213-8587(20)30115-7
   PubMed Web of Science ®Google Scholar
• Pacini F, Castagna MG. Approach to and treatment of differentiated thyroid carcinoma. Med Clin North Am. 2012;96(2):369–383. doi:10.1016/j.mcna.2012.01.002
   PubMed Web of Science ®Google Scholar
• Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. doi:10.1089/thy.2015.0020
   PubMed Web of Science ®Google Scholar
• Jin BJ, Kim MK, Ji YB, Song CM, Park JH, Tae K. Characteristics and significance of minimal and maximal extrathyroidal extension in papillary thyroid carcinoma. Oral Oncol. 2015;51(8):759–763. doi:10.1016/j.oraloncology.2015.05.010
   PubMed Web of Science ®Google Scholar
• Diker-Cohen T, Hirsch D, Shimon I, et al. Impact of minimal extra-thyroid extension in differentiated thyroid cancer: systematic review and meta-analysis [published online ahead of print, 2018 Mar 1]. J Clin Endocrinol Metab. 2018. doi:10.1210/jc.2018-00081
   Web of Science ®Google Scholar
• Shaha AR, Migliacci JC, Nixon IJ, et al. Stage migration with the new American Joint Committee on Cancer (AJCC) staging system (8th edition) for differentiated thyroid cancer. Surgery. 2019;165(1):6–11. doi:10.1016/j.surg.2018.04.078
   PubMed Web of Science ®Google Scholar
• Bortz MD, Kuchta K, Winchester DJ, Prinz RA, Moo-Young TA. Extrathyroidal extension predicts negative clinical outcomes in papillary thyroid cancer. Surgery. 2021;169(1):2–6. doi:10.1016/j.surg.2020.04.003
   PubMed Web of Science ®Google Scholar
• Mercante G, Frasoldati A, Pedroni C, et al. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid. 2009;19(7):707–716. doi:10.1089/thy.2008.0270
   PubMed Web of Science ®Google Scholar
• Arora N, Turbendian HK, Scognamiglio T, et al. Extrathyroidal extension is not all equal: implications of macroscopic versus microscopic extent in papillary thyroid carcinoma. Surgery. 2008;144(6):942–948. doi:10.1016/j.surg.2008.07.023
   PubMed Web of Science ®Google Scholar
• Shin JH, Ha TK, Park HK, et al. Implication of minimal extrathyroidal extension as a prognostic factor in papillary thyroid carcinoma. Int J Surg. 2013;11(9):944–947. doi:10.1016/j.ijsu.2013.06.015
   PubMed Web of Science ®Google Scholar
• Cracchiolo JR, Wong RJ. Management of the lateral neck in well differentiated thyroid cancer. Eur J Surg Oncol. 2018;44(3):332–337. doi:10.1016/j.ejso.2017.06.004
   PubMed Web of Science ®Google Scholar
• Wang LY, Nixon IJ, Patel SG, et al. Operative management of locally advanced, differentiated thyroid cancer. Surgery. 2016;160(3):738–746. doi:10.1016/j.surg.2016.04.027
   PubMed Web of Science ®Google Scholar
• Fleeman N, Houten R, Chaplin M, et al. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC Cancer. 2019;19(1):1209. doi:10.1186/s12885-019-6369-7
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–630. doi:10.1056/NEJMoa1406470
   PubMed Web of Science ®Google Scholar
• Haugen BR, Sawka AM, Alexander EK, et al. American thyroid association guidelines on the management of thyroid nodules and differentiated thyroid cancer task force review and recommendation on the proposed renaming of encapsulated follicular variant papillary thyroid carcinoma without invasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Thyroid. 2017;27(4):481–483. doi:10.1089/thy.2016.0628
   PubMed Web of Science ®Google Scholar
• Van Nostrand D. Radioiodine refractory differentiated thyroid cancer: time to update the classifications. Thyroid. 2018;28(9):1083–1093. doi:10.1089/thy.2018.0048
   PubMed Web of Science ®Google Scholar
• Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(12):1856–1883. doi:10.1093/annonc/mdz400
   PubMed Web of Science ®Google Scholar
• Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium [published correction appears in Eur J Endocrinol. 2006 Aug;155(2):385]. Eur J Endocrinol. 2006;154(6):787–803. doi:10.1530/eje.1.02158
   PubMed Web of Science ®Google Scholar
• Mitchell AL, Gandhi A, Scott-Coombes D, Perros P. Management of thyroid cancer: United Kingdom national multidisciplinary guidelines. J Laryngol Otol. 2016;130(S2):S150–S160. doi:10.1017/S0022215116000578
   PubMed Web of Science ®Google Scholar
• Thyroid Cancer Working Group C. Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer 2018 (English version). Chin J Cancer Res. 2019;31(1):99–116. doi:10.21147/j.issn.1000-9604.2019.01.06
   PubMed Web of Science ®Google Scholar
• Ito Y, Onoda N, Okamoto T. The revised clinical practice guidelines on the management of thyroid tumors by the Japan associations of endocrine surgeons: core questions and recommendations for treatments of thyroid cancer. Endocr J. 2020;67(7):669–717. doi:10.1507/endocrj.EJ20-0025
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China. Diagnosis and treatment guidelines for thyroid cancer (2018 edition). Chin Arch Gener Surg. 2019;13(01):1–15.
   Google Scholar
• Youngwirth LM, Adam MA, Scheri RP, Roman SA, Sosa JA. Extrathyroidal extension is associated with compromised survival in patients with thyroid cancer. Thyroid. 2017;27(5):626–631. doi:10.1089/thy.2016.0132
   PubMed Web of Science ®Google Scholar
• Oliveira KJ, Chiamolera MI, Giannocco G, Pazos-Moura CC, Ortiga-Carvalho TM. Thyroid function disruptors: from nature to chemicals [published online ahead of print, 2018 Jul 13]. J Mol Endocrinol. 2018;JME-18–0081. doi:10.1530/JME-18-0081
   Web of Science ®Google Scholar
• Mete O, Rotstein L, Asa SL. Controversies in thyroid pathology: thyroid capsule invasion and extrathyroidal extension. Ann Surg Oncol. 2010;17(2):386–391. doi:10.1245/s10434-009-0832-7
   PubMed Web of Science ®Google Scholar
• Kowalski LP, Filho JG. Results of the treatment of locally invasive thyroid carcinoma. Head Neck. 2002;24(4):340–344. doi:10.1002/hed.10058
   PubMed Web of Science ®Google Scholar
• Lee DY, Hwang SM, An JH, et al. Predicting extrathyroidal extension in patients with papillary thyroid microcarcinoma according to a BRAF mutation. Clin Exp Otorhinolaryngol. 2017;10(2):174–180. doi:10.21053/ceo.2015.01655
   PubMed Web of Science ®Google Scholar
• Tran B, Roshan D, Abraham E, et al. An analysis of the American joint committee on cancer 8th edition t staging system for papillary thyroid carcinoma. J Clin Endocrinol Metab. 2018;103(6):2199–2206. doi:10.1210/jc.2017-02551
   PubMed Web of Science ®Google Scholar
• Kim HI, Hyeon J, Park SY, et al. Impact of extranodal extension on risk stratification in papillary thyroid carcinoma. Thyroid. 2019;29(7):963–970. doi:10.1089/thy.2018.0541
   PubMed Web of Science ®Google Scholar
• Abraham E, Tran B, Roshan D, et al. Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence. ANZ J Surg. 2018;88(11):1193–1197. doi:10.1111/ans.14490
   PubMed Web of Science ®Google Scholar
• Biondi B, Cooper DS. Thyroid hormone suppression therapy. Endocrinol Metab Clin North Am. 2019;48(1):227–237. doi:10.1016/j.ecl.2018.10.008
   PubMed Web of Science ®Google Scholar
• Clement SC, Peeters RP, Ronckers CM, et al. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma--a systematic review. Cancer Treat Rev. 2015;41(10):925–934. doi:10.1016/j.ctrv.2015.09.001
   PubMed Web of Science ®Google Scholar